Transgene Biotek (BOM:526139) Net Margin %: -838.53% (As of Mar. 2026)


BOM:526139 Transgene Biotek Ltd BOM:526139
47 GF Score
Price ₹3.11
GF Value ₹6.51
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Transgene Biotek Net Margin %?

Transgene Biotek BOM:526139 +2.64% 47 Net Margin % is -838.53% as of Mar. 2026. GuruFocus rates BOM:526139 with a GF Score™ of 47/100 and a GF Value™ of ₹6.51 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Transgene Biotek ranks worse than 76.06% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Transgene Biotek's Net Income for the three months ended in Mar. 2026 was ₹-4.57 Mil. Transgene Biotek's Revenue for the three months ended in Mar. 2026 was ₹0.55 Mil. Therefore, Transgene Biotek's net margin for the quarter that ended in Mar. 2026 was -838.53%.

The historical rank and industry rank for Transgene Biotek's Net Margin % or its related term are showing as below:

BOM:526139' s Net Margin % Range Over the Past 10 Years
Min: -28700.43   Med: -8530.54   Max: -259.34
Current: -782.25

BOM:526139's Net Margin % is ranked worse than
76.06% of 944 companies
in the Biotechnology industry
Industry Median: -88.815 vs BOM:526139: -782.25

Transgene Biotek  (BOM:526139) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Transgene Biotek Net Margin % Related Terms

Transgene Biotek Net Margin % Historical Data

* Premium members only.

The historical data trend for Transgene Biotek's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Biotek Net Margin % Chart

Transgene Biotek Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11,997.69 -10,904.90 -279.05 -259.34 -782.62

Transgene Biotek Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -932.16 -876.16 -735.61 -685.87 -838.53

BOM:526139 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Transgene Biotek's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgene Biotek Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene Biotek's Net Margin % distribution charts can be found below:

* The bar in red indicates where Transgene Biotek's Net Margin % falls into.


BOM:526139
47GF Score
Transgene Biotek Ltd BOM:526139
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene Biotek Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Transgene Biotek's Net Margin for the fiscal year that ended in Mar. 2026 is calculated as

Net Margin=Net Income (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-16.529/2.112
=-782.62 %

Transgene Biotek's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.57/0.545
=-838.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -838.53% mean?
Transgene Biotek (BOM:526139) has a Net Margin % of -838.53% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Transgene Biotek and its competitors. According to the industry distribution chart, Transgene Biotek ranks #718 out of 944 companies in the Biotechnology industry, placing it in the top 76.1%.
Is Transgene Biotek's Net Margin % too high?
Transgene Biotek's current Net Margin % is -838.53%. Based on the distribution chart, Transgene Biotek ranks #718 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Transgene Biotek has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Transgene Biotek's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgene Biotek ranks #718 out of 944 companies for Net Margin %. This places Transgene Biotek in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Transgene Biotek and its competitors. Transgene Biotek's current Net Margin % is -838.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene Biotek stock overvalued right now?
Based on GuruFocus' analysis, Transgene Biotek (BOM:526139) is currently considered Possible Value Trap. The stock's GF Value™ is ₹6.51, compared to a current price of ₹3.11 — trading 52.2% below its estimated fair value. The current Net Margin % is -838.53%. Transgene Biotek's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Transgene Biotek (BOM:526139), the current Net Margin % is -838.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgene Biotek (BOM:526139) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹3.11 is trading 52.2% below its estimated GF Value™ of ₹6.51. GuruFocus considers Transgene Biotek to be Possible Value Trap.

Key valuation signals for BOM:526139:

  • Net Margin %: -838.53%
  • GF Value™: ₹6.51 vs. price of ₹3.11 (52.2% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Biotek Business Description

Address Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.
47GF Score

Get the complete analysis for BOM:526139

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3.11
Price
₹6.51
GF Value